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benzodiazepines in the Netherlands:
does it make a difference?
Boudewijn J Kollen1*, Willem Jan van der Veen2, Feikje Groenhof1, Gé A Donker1,3 and Klaas van der Meer1Abstract
Background: In an attempt to control chronic benzodiazepine use and its costs in the Netherlands, health care
insurance reimbursement of this medication was stopped on January 1st 2009. This study investigates whether
benzodiazepine prescriptions issued by general practitioners changed during the first two years following
implementation of this regulation.
Methods: Registry study based on data from all benzodiazepine users derived from the Registration Network
Groningen. This general practice-based research network collects longitudinal data on the primary care
administered to about 30,000 patients. Based on the number of quarterly accumulated prescription days,
a comparison was made of benzodiazepine prescriptions issued between 2007/2008 and 2009/2010. Also
investigated was which type of user (i.e. short-term or long-term) showed the most change.
Results: Information on benzodiazepine prescriptions among 5,200 patients from 16 consecutive trimesters
between 2007 and 2010 was available for analysis. A significant reduction in prescription days was observed
between 2007/2008 and 2009/2010. Overall, an estimated 1.73 (CI:-1.94 to -1.53; p<0.001) days were less prescribed
per trimester after the termination of reimbursement. In particular, short-term users experienced a reduction in
prescription days in 2009 and 2010. The number of long-term users decreased by 2.3%, while the number of
individuals that did not use increased by 4.2%.
Conclusions: A total reduction of almost 14 prescription days was observed over eight trimesters after
implementation of the regulation to terminate the reimbursement of benzodiazepines. Short-term users were
mainly responsible for this reduction in prescription days in 2009 and 2010. Although long-term users did not alter
their benzodiazepine use in 2009 and 2010, the number of long-term users decreased slightly.Background
Benzodiazepines are frequently prescribed to patients
suffering from anxiety, nervousness or sleep problems. In
2007, over 10 million prescriptions of benzodiazepines
for 1.8 million individuals were issued in the Netherlands.
The general practitioner (GP) is responsible for most of
these prescriptions [1].
Although it is generally recommended to use benzo-
diazepines for only a brief period, a substantial propor-
tion of patients become long-term chronic users of this* Correspondence: b.j.kollen@umcg.nl.
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reproduction in any medium, provided the ormedication [2]. Long-term use carries the risk of depend-
ence, cognitive impairment, accidents and falls, especially
in the elderly [3]. In the Dutch population, this long-
term use of benzodiazepines has remained persistent
over the years (1992–2002) despite efforts to reduce its
use and renewal of the guidelines [4]. Even attempts by
community pharmacies in collaboration with GPs to sub-
stantially reduce the long-term use of benzodiazepines
failed to succeed [5].
In the Netherlands, in an attempt to impose a reduction
in benzodiazepine use, health care insurance reimburse-
ment of this medication was stopped on January 1st 2009.
Although this regulation was primarily implemented to
reduce or prevent the long-term use and addictive effects
of this medication, it also served to diminish the coststd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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from long-term users, also first and short-term users
were affected by this regulation.
Not all patients were deprived of reimbursement for
this medication. The administration of benzodiazepines
remained funded for individuals who are dependent on
this medication in the absence of an adequate alterna-
tive. This applies to patients that use benzodiazepines
to curtail epileptic seizures, to individuals with anxiety
disorders in which at least two anti-depressants fail to
ameliorate symptoms, and to patients with multiple
psychiatric conditions that necessitate the administra-
tion of high doses of benzodiazepines. Finally, palliative
sedation used in terminal care is also exempted from
this regulation, as are patients that require diazepam
medication for muscular spasms resulting from neuro-
logical disorders.
In preparing for implementation of this regulation,
physicians and pharmacists were asked to inform their
patients that reimbursement of this medication would
be terminated in 2009 and that those who continue to
use benzodiazepines would bear the costs of purchasing
the medication. Physicians were encouraged to discuss
discontinuation with their patients as a viable option
and offer suitable alternatives. Discontinuation of this
medication would then best be carried out gradually in
close collaboration with the physician and pharmacist.
This reimbursement restriction has led to a moderate
decrease in the number of incident diagnoses and initi-
ation of benzodiazepine use in patients with newly diag-
nosed anxiety or sleeping disorders in 2009 [6]. However,
whether the overall use (prevalence) has changed over a
longer period remains unknown.
In the present study, we investigated whether benzo-
diazepine use changed after termination of the reim-
bursement of the medication. The number of quarterly
accumulated prescription days for each benzodiazepine
user was compared between the 2007/2008 and 2009/
2010 periods. Prescription days were defined as the num-
ber of days that benzodiazepines were prescribed during
each trimester.
We anticipated a reduction in prescription days during
2009 and 2010. In order to explore which type of user
experienced the most change, the users were categorized
into initial, short-term and long-term users. We hypothe-
sized that long-term users would show the most change.
Methods
Data from all benzodiazepine users in the Registration
Network Groningen (RNG) were obtained. This general
practice-based research network was established in 1989
and consists, at present, of three large group practices
situated in the north-eastern part of the Netherlands.
Participating GPs (n=20) register all their primary care.In this way, the annual care of about 30,000 regular
patients is recorded longitudinally. All consultations,
with the reasons for encounter as well as diagnoses and
prescriptions, are recorded. Morbidity data are also elec-
tronically registered using the International Classification
of Primary Care (ICPC) and each prescribed medication
is fitted with an ICPC-based code. Prescriptions are
automatically classified with an Anatomical Therapeutic
Chemical (ATC) code. The benzodiazepines that are
affected by the regulation are classified in the benzodiaze-
pines derivatives category (ATC N05BA and N05CD) and
benzodiazepines-related drugs (ATC N05CF).
This study was approved by the review board of the
University Medical Centre of Groningen.Data analyses
The characteristics of patients from a particular GP and
their observations usually differ slightly from those of
patients from other GPs. As a consequence, GP-related
patient information is to some degree clustered. The ana-
lysis of such data requires the implementation of multi-
level statistical methods that adjust for this clustering.
Linear multilevel analysis (MLA) was conducted using
MLwiN 2.23 to determine whether a change occurred in
the number of prescription days. Multilevel models are
hierarchical systems that estimate regression coefficients
and their related variance components while at the same
time adjust for the dependency of observations. The first
level was defined as observation, the second level as
patient, and the third level as GP. The iterative general-
ized least squares algorithm was used to estimate the
regression coefficients and the likelihood ratio test to
evaluate the necessity for allowing random intercept
and regression coefficients into the model, while the
Wald test was used to obtain a p value for each regres-
sion coefficient [7]. Outcome scores were plotted to
check for compliance with model assumptions. For all
tests, a two-tailed significance level of p<0.05 was used.
In addition, to investigate whether the changes in
benzodiazepine consumption after termination of reim-
bursement depended on the type of user, users were
categorized based on their number of quarterly registered
prescription days. We identified initial users (individuals
who did not use in the trimester prior to starting this
medication), short-term users (individuals with less than
60 prescription days in a particular quarter), long-term
users (individuals with 60 or more prescription days),
quitters (individuals who were users in the trimester
prior to discontinuing this medication), and a category
unknown adapted from [1]. When no information was
available in the preceding quarter, initial users and quit-
ters could not be identified and were excluded from the
analysis.
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terms were fitted in the multilevel regression model to
investigate whether the number of prescription days was
dependent on the period of registration (2007/2008 ver-
sus 2009/2010).
In this analysis, an initial user could not also be classi-
fied as short or long-term user, even though being an
initial and short or long-term user is not mutually exclu-
sive. Because this compatibility problem affects short-
term and long-term rates, a supplementary analysis was
conducted to determine the real contribution of short-
term and long-term users to the change in prescription
rates before and after implementation of the regulation.
In this analysis we used all information on short-term
and long-term users, thus ignoring available information
on initial users and quitters. In other words, the number
of prescription days was compared between 2007/2008
and 2009/2010 for all short-term and long-term users
categorized independently of the information in the pre-
ceding quarter.
Results
Information on benzodiazepine prescriptions in 5,200
patients over a 4-year period (2007–2010) and sub-
divided into 16 trimesters was available for analysis. Of
all users, 63% was female (n=3,259) and 37% male
(n=1,941). The mean age during this study period was 53
(±18.8) years; 54 (±19.5) for females and 52 (±17.4) years
for males. The percentage of missing values of the out-
come variable, i.e. number of prescription days, was
10.6% (8.5% in 2007/2008 and 12.7% in 2009/2010). On
average, benzodiazepines were prescribed during each
trimester for 15.57 days in 2007/2008 and 13.45 days
in the 2009/2010 (Table 1). Table 1 also presents the
number of each type of user for each trimester in this
open cohort.
Multilevel analysis revealed a significant reduction in
prescription days between 2007/2008 and 2009/2010.
On average, compared to before implementation, there
was an estimated 1.73 (CI:-1.94 to -1.53; p<0.001) reduc-
tion in prescription days during each trimester after
implementation of the regulation. This reduction can be
explained by changes occurring at all three levels, i.e.
within (p<0.001) and between patients (p<0.001) and
between GPs (p=0.02). The explained variance of this
association is 0.4%.
No differences in gender (p=0.38) or person-time
(p=0.28) before and after stopping reimbursement was
found. This indicates that in this dynamic cohort person-
time did not accrue differently between study periods
as a result of dynamic inclusion and attrition rates.
Across all trimesters, a pattern is visible of increasing
use of benzodiazepines towards the end of each year
and towards the end of the 2007/2008 and 2009/2010periods, with a sharp decline in prescription days be-
tween the last quarter of 2008 and first quarter of 2009
(Figure 1).
Overall, in 2009/2010 the mean number of individuals
that did not use benzodiazepines (i.e. no users and quit-
ters) had increased by 4.2% compared with the 2007/
2008 levels, while the mean number of long-term users
decreased by 2.3%. The mean number of initial users
and short-term users showed a marginal decrease of
0.8% and 1.1%, respectively (Table 1).
At a benzodiazepine user and non-user level, the initial
users, short and long-term users all showed less pre-
scription days after implementation of the regulation.
On average, long-term users experienced the greatest re-
duction (i.e. 1.4 days; p<0.001), while short-term users
showed a reduction of 1.1 days (p<0.001) and initial
users less than 1 day (p=0.001) per trimester (Table 2).
However, when considering all available information on
short-term and long-term users (some of whom were
identified as initial users in the previous analysis) we
found that between 2007/2008 and 2009/2010 the num-
ber of prescription days decreased significantly from
19.88 to 18.96 days during each trimester (-0.91, CI:-1.17
to -0.66; p<0.001) in short-term users. However, no sig-
nificant decrease in benzodiazepine use was observed in
long-term users (-0.14, CI:-0.48 to 0.20; p=0.41). In this
supplementary analysis, almost all initial users are classi-
fied as short-term users (97.5% in 2007/2008 and 98.3%
in 2009/2010) and the reduction in prescription days for
initial users is added mainly to that of the short-term
users. The absolute difference in number of prescription
days per trimester between short-term and long-term
users increased by almost 1 day (0.96, CI:0.33 to 1.58;
p=0.003) from 47.63 prescription days in 2007 and 2008
to 48.59 days in 2009 and 2010.
Discussion
This study demonstrates a significant decrease of 1.7 days
in the number of prescription days per trimester between
2007/2008 and 2009/2010. Although it is likely that the
termination of reimbursement is partly responsible for
this reduction in prescription days, the present study
design is not suitable to establish a causal effect. More-
over, given the limited explained variance of the associ-
ation, other factors have also contributed to this change.
Furthermore, based on the magnitude of the large num-
ber of benzodiazepine users, significance is relatively easy
to obtain in a sample of this size. More importantly,
should this significant reduction in prescription days also
be considered a relevant reduction? This is debatable as
this reduction represents about 10% of the mean number
of prescription days per trimester in the 2007/2008
period. Moreover, the observed increase in prescription
rates towards the end of 2008 may be partially due to
Table 1 Mean number of prescription days and (mean) number of type of users between 2007 and 2010
Trimesters
2007 2008 Mean (%) 2009 2010 Mean (%) Difference
means (p)1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
Mean number of
prescription days
12.98ǂ 15.45 15.65 15.94 15.51 16.14 15.98 16.90 15.57 13.34 13.03 13.05 13.38 13.23 13.56 13.61 14.48 13.46 2.11
Type of user
no user ǂ 2642 2614 2608 2586 2619 2623 2532 2603 (56.2) 2597 2698 2802 2704 2645 2653 2642 2541 2660 (60.0) -56.82 (<0.001)
initial ǂ 458 404 449 417 399 389 435 422 (9.1) 270 365 363 429 378 367 351 408 366 (8.3) 55.20 (<0.001)
short-term ǂ 612 604 624 636 620 642 662 629 (13.6) 762 513 518 521 559 514 533 509 554 (12.5) 74.95 (<0.001)
long-term ǂ 556 591 580 580 594 592 606 586 (12.7) 454 461 445 447 445 474 467 483 460 (10.4) 126.07 (<0.001)
Quitter ǂ 365 427 385 431 404 364 345 389 (8.4) 475 496 357 340 390 378 342 340 390 (8.8) -1.04 (<0.046)
Total ǂ 4633 4640 4646 4650 4636 4610 4580 4629 (100) 4558 4533 4485 4441 4417 4386 4335 4281 4430 (100)
Supplementary
analysis of short
vs. long term users
short-term 1131 1100 1031 1109 1089 1057 1073 1138 1091 1071 904 909 981 972 916 922 949 953 138
long-term 459 583 615 598 602 628 617 626 591 467 478 465 459 460 489 483 509 476 114.75
Total 1590 1683 1646 1707 1691 1685 1690 1764 1682 1538 1382 1374 1440 1432 1405 1405 1458 1429
ǂ The first trimester of 2007 is omitted due to or affected by the unavailability of information of prescription days from the preceding trimester. Because of this, no information on initial users and quitters was
available for the first trimester of 2007. As a consequence, presenting information on short-term and long-term users would generate an overestimation when compared to the information on short-term and



















Figure 1 Mean number of prescription days of benzodiazepines for each trimester between 2007 and 2010 and corresponding
confidence interval. The first trimester of 2007 is omitted due to the unavailability of information of prescription days from the preceding
trimester.
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through the first months of 2009. As a consequence, the
ensuing sharp decline in prescription rate at the beginning
of 2009 is likely to be more pronounced. In the literature
more dramatic reductions in prescription rates have been
reported of up to 60% over a one-year period following
their regulation [8]. In our study, the prescription rate
started to rebound somewhat during the second year fol-
lowing the regulation. Therefore, a more realistic consid-
eration of the long-term effects of the regulation to curtail
the prescription rate of benzodiazepines can probably be
attained over a prolonged period (e.g. 5 years).
Although this medication is relatively inexpensive to
purchase, the economic gain as a result of this reduction
may still be substantial given its widespread use. An up-
ward trend can be observed in 2009 and 2010, especiallyTable 2 Mean number of estimated quarterly prescription







initial 16.98 16.31 -0.68 (-1.07–-0.28) 0.001
short-term 25.08 24.02 -1.05 (-1.39–-0.71) <0.001
long-term 74.54 73.15 -1.40 (-1.75–-1.04) <0.001
CI=confidence interval.towards the end of the registration period (Figure 1). It
is not inconceivable that the number of prescription
days for benzodiazepine may return to the 2008 level in
the coming years.
As demonstrated in this study, initial users, short-term
and long-term users contributed proportionally to this
reduction in prescription days. Unlike long-term users
and initial users, short-term users experienced a brief dip
in their mean prescription days between the last quarter
of 2008 and the second quarter of 2009 (Figure 2).
Overall, the reduction in prescription days coincided
with a reduction in the number of users, i.e. the number
of individuals that did not use increased and the number
of long-term users decreased.
However, when initial users are considered as either
short-term or long-term users, a different picture emerges
in that the reduction in prescription days in 2009/2010 is
less pronounced and was only observed among short-term
users. The number of prescription days among long-term
users showed no significant change. Therefore, the pri-
mary objective of this regulation to substantially reduce
long-term use may not have materialized.
Limitations
In this study, no effort was made to identify substitution
effects. These effects occur when subscriptions are issued
Figure 2 Course of quarterly accumulated prescription days of benzodiazepines for long-term users (upper line), short-term users
(middle line) and initial users (lower line) between 2007 and 2010. The first trimester of 2007 is omitted due to the unavailability of
information of prescription days from the preceding trimester.
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pines. This, in turn, could have biased our outcome as
current no users in our population may have been users
of these other drugs. This effect was observed in the
study of Weintraub et al. who investigated the conse-
quences of the 1989 New York State triplicate benzodi-
azepine prescription regulations [8]. In addition to a
decrease in the number of prescriptions for benzodiaze-
pines, they reported a negative impact of the regulations,
i.e. an increase in prescriptions for alternative medica-
tions [8]. Moreover, in our open cohort, inclusion and
attrition rates of patients varied during the course of the
study; this resulted in absent registrations in the general
practice-based research network and missing values in
the dataset. Whether individuals with missing values
used benzodiazepines prescribed elsewhere is uncertain.
Also, in the present study, benzodiazepine “use” was used
as an approximation for benzodiazepine “prescriptions”.
However, this may not always be accurate as in fact not
all prescriptions of benzodiazepines may have led to their
consumption. Similarly, in our study we assumed that
“mean days of prescription” corresponds with the mean
number of pills consumed; this may not be accurate. Fur-
thermore, we did not define the assumed average main-
tenance dose per day for the benzodiazepines prescribedin the present study. As a result, we cannot rule out that
attempts to lower the dose may have played a role in the
decrease of the prescription days described as defined
daily dose.
Finally, information on the first quarter of 2007 was
incomplete because the effects of prescriptions issued in
the last quarter of 2006 are missed in our analysis.
Therefore, the estimated decrease of 1.7 days in the num-
ber of prescription days per trimester between 2007/2008
and 2009/2010 may represent a slight underestimation.
Conclusions
A total reduction of almost 14 prescription days (repre-
senting 1.73 days over 8 trimesters) was observed over a
two-year period after implementation of the regulation to
terminate the reimbursement of benzodiazepines. Short-
term users were mainly responsible for this reduction in
prescription days in 2009 and 2010. Although long-term
users did not alter their benzodiazepine use in 2009 and
2010, the number of long-term users decreased slightly.
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